## Nuria GonzÃ;lez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2436264/publications.pdf

Version: 2024-02-01

516710 677142 21 911 16 22 citations h-index g-index papers 22 22 22 1655 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses. Journal of Virology, 2022, 96, JVI0134321.	3.4	10
2	Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence. Nature Communications, 2019, 10, 2355.	12.8	116
3	CCR5 structural plasticity shapes HIV-1 phenotypic properties. PLoS Pathogens, 2018, 14, e1007432.	4.7	27
4	Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors. PLoS ONE, 2018, 13, e0193773.	2.5	24
5	Different Expression of Interferon-Stimulated Genes in Response to HIV-1 Infection in Dendritic Cells Based on Their Maturation State. Journal of Virology, 2017, 91, .	3.4	6
6	Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization. PLoS ONE, 2017, 12, e0186602.	2.5	20
7	Guidelines for cloning, expression, purification and functional characterization of primary HIV-1 envelope glycoproteins. Journal of Virological Methods, 2016, 236, 184-195.	2.1	6
8	Hydroxytyrosol. Aids, 2016, 30, 2767-2776.	2.2	23
9	Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1. Journal of Antimicrobial Chemotherapy, 2015, 70, 1833-1842.	3.0	56
10	HIV-1 exploits CCR5 conformational heterogeneity to escape inhibition by chemokines. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 9475-9480.	7.1	61
11	Characterization of LEDGF/p75 Genetic Variants and Association with HIV-1 Disease Progression. PLoS ONE, 2012, 7, e50204.	2.5	10
12	A cell-to-cell HIV transfer assay identifies humoral responses with broad neutralization activity. Vaccine, 2011, 29, 5250-5259.	3.8	38
13	Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVACO2). Vaccine, 2011, 29, 8309-8316.	3.8	70
14	A Therapeutic Dendritic Cell-Based Vaccine for HIV-1 Infection. Journal of Infectious Diseases, 2011, 203, 473-478.	4.0	105
15	Broadly Neutralizing Antibodies and their Significance for HIV-1 Vaccines. Current HIV Research, 2010, 8, 602-612.	0.5	12
16	SDF-1/CXCL12 Production by Mature Dendritic Cells Inhibits the Propagation of X4-Tropic HIV-1 Isolates at the Dendritic Cell-T-Cell Infectious Synapse. Journal of Virology, 2010, 84, 4341-4351.	3.4	25
17	A sensitive phenotypic assay for the determination of human immunodeficiency virus type 1 tropism. Journal of Antimicrobial Chemotherapy, 2010, 65, 2493-2501.	3.0	35
18	Guatemalan plants extracts as virucides against HIV-1 infection. Phytomedicine, 2008, 15, 520-524.	5.3	20

## Nuria GonzÃilez

#	Article	IF	CITATIONS
19	Association between stromal cell-derived factor 1 chemokine gene variant and radiographic progression of rheumatoid arthritis. Arthritis and Rheumatism, 2005, 52, 354-356.	6.7	26
20	Therapeutic Immunization with Dendritic Cells Loaded with Heatâ€Inactivated Autologous HIVâ€1 in Patients with Chronic HIVâ€1 Infection. Journal of Infectious Diseases, 2005, 191, 1680-1685.	4.0	147
21	Functional Characterization of SDF-1 Proximal Promoter. Journal of Molecular Biology, 2005, 348, 43-62.	4.2	72